Vicapsys Life Sciences, Inc. VICP

Annual Quarterly

No annual revenue total was found in VICAPSYS LIFE SCIENCES, INC.'s SEC filings.

Vicapsys Life Sciences, Inc. (VICP) files with the SEC under industry code 2834, Pharmaceutical Preparations.

Revenue
—
Net income (TTM)
$-1.35M
-24.8% vs year-ago TTM
Operating cash flow (TTM)
$-125,741
+62.2% vs year-ago TTM
Free cash flow
—
EPS (TTM)
$-0.04
Dividend per share
None
Shares outstanding
32.07M
+2.8% vs prior year
Net cash
$-9,290
FY 2023
Operating margin
—

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
VICP (OTC)
Fiscal year ends
December 31
Incorporated in
FL
Headquarters
Cumming, GA
SEC filer status
Non-accelerated filer, Smaller reporting company, Emerging growth company
SEC CIK
1468639
Former names
SSGI, INC. (until Nov 7, 2016)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Key figures

Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.

FY 2023
Dec 31, 2023
FY 2022
Dec 31, 2022
FY 2021
Dec 31, 2021
FY 2020
Dec 31, 2020
Operating income
-$1.0M
-$984,790
-$336,871
—
Net income
-$1.2M
-$984,790
-$236,871
-$765,844
Diluted EPS
-$0.03
—
—
—
Operating cash flow
-$417,524
-$238,197
-$443,974
-$262,897
Total assets
$39,656
$72,021
$594,313
$404,118
Stockholders' equity
-$1.9M
-$950,791
-$121,651
-$449,106
Cash and investments
$9,422
$14,097
$217,295
$1,269
Total debt
$18,712
—
—
—

Recent SEC filings

Form Description Filed Period
10-Q Quarterly report Jan 10, 2025 Sep 30, 2024
10-Q Quarterly report Jan 10, 2025 Jun 30, 2024
10-Q Quarterly report Jan 10, 2025 Mar 31, 2024
10-K Annual report Oct 21, 2024 Dec 31, 2023
8-K Current report
Material agreement, New debt
 Dec 27, 2023 Dec 26, 2023
10-Q Quarterly report Nov 14, 2023 Sep 30, 2023

All 92 Vicapsys Life Sciences, Inc. SEC filings

Source: SEC EDGAR filings. This is company-reported data, not investment advice.